TOP TEN perturbations for 1318_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1318_at
Selected probe(set): 210371_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1318_at (210371_s_at) across 6593 perturbations tested by GENEVESTIGATOR:

glioma study 27 (glioblastoma, NOS) / glioma study 27 (pilocytic astrocytoma)

Relative Expression (log2-ratio):2.7970047
Number of Samples:4 / 2
Experimental glioma study 27 (glioblastoma, NOS)
Primary tumor samples from resected brain tissues of patients with glioblastoma, NOS(WHO grade IV astrocytoma).
Control glioma study 27 (pilocytic astrocytoma)
Primary tumor samples from resected brain tissues of patients with pilocytic astrocytoma (WHO grade I astrocytoma).

Alzheimer's disease study 7 / normal pyramidal neuron (hippocampus)

Relative Expression (log2-ratio):-2.7469378
Number of Samples:10 / 12
Experimental Alzheimer's disease study 7
Pyramidal neurons collected from the CA1 region of the hippocampus of clinically and neuropathologically classified late-onset Alzheimer´s disease afflicted individuals. Subjects in this group had a Braak stage of V or VI with a CERAD score of moderate or frequent.
Control normal pyramidal neuron (hippocampus)
Pyramidal neurons collected from the CA1 region of the hippocampus of clinically classified as neurologically normal individuals. Subjects in this group had a Braak stage ranging from I to II with a infrequent Consortium to Establish a Registry for Alzheimer's Disease (CERAD) neuritic plaque density.

renal cell carcinoma study 6 (chromophobe type) / normal kidney tissue

Relative Expression (log2-ratio):-2.7204113
Number of Samples:4 / 2
Experimental renal cell carcinoma study 6 (chromophobe type)
Tumor tissue samples from the kidney of patients with chromophobe renal cell carcinoma (cRCC).
Control normal kidney tissue
Normal fetal kidney tissue samples.

oncolytic herpes simplex virus study 2 / mock infected peripheral nerve sheath tumor (S462) cell sample

Relative Expression (log2-ratio):-2.5769386
Number of Samples:3 / 3
Experimental oncolytic herpes simplex virus study 2
Human malignant peripheral nerve sheath tumor (S462) cells infected with G207, an ICP34.5-deleted oncolytic herpes simplex virus (oHSV) for 6 hours.
Control mock infected peripheral nerve sheath tumor (S462) cell sample
Human malignant peripheral nerve sheath tumor (S462) cells mock infected for 6 hours.

expO kidney cancer study 1 (renal cell carcinoma, sarcomatoid; primary) / expO kidney cancer study 1 (neoplasm, malignant; primary)

Relative Expression (log2-ratio):2.35948
Number of Samples:3 / 2
Experimental expO kidney cancer study 1 (renal cell carcinoma, sarcomatoid; primary)
Primary tumor tissue samples obtained from the kidney of patients with renal cell carcinoma, sarcomatoid.
Control expO kidney cancer study 1 (neoplasm, malignant; primary)
Primary tumor tissue samples obtained from the kidney of patients with malignant neoplasm.

expO kidney cancer study 1 (clear cell adenocarcinoma, NOS; metastatic) / expO kidney cancer study 1 (neoplasm, malignant; primary)

Relative Expression (log2-ratio):2.1930332
Number of Samples:3 / 2
Experimental expO kidney cancer study 1 (clear cell adenocarcinoma, NOS; metastatic)
Metastatic tumor tissue obtained from a patient with primary clear cell adenocarcinoma (NOS) of the kidney.
Control expO kidney cancer study 1 (neoplasm, malignant; primary)
Primary tumor tissue samples obtained from the kidney of patients with malignant neoplasm.

expO kidney cancer study 1 (renal cell carcinoma, NOS; primary) / expO kidney cancer study 1 (neoplasm, malignant; primary)

Relative Expression (log2-ratio):2.1061153
Number of Samples:5 / 2
Experimental expO kidney cancer study 1 (renal cell carcinoma, NOS; primary)
Primary tumor tissue samples obtained from the kidney of patients with renal cell carcinoma (NOS).
Control expO kidney cancer study 1 (neoplasm, malignant; primary)
Primary tumor tissue samples obtained from the kidney of patients with malignant neoplasm.

nephroblastoma study 2 / normal kidney tissue

Relative Expression (log2-ratio):2.0797586
Number of Samples:4 / 3
Experimental nephroblastoma study 2
Tumor tissue samples from the kidney of patients with Wilms’ tumor.
Control normal kidney tissue
Normal adult kidney tissue samples.

expO kidney cancer study 1 (renal cell carcinoma, sarcomatoid; primary) / expO kidney cancer study 1 (granular cell carcinoma; primary)

Relative Expression (log2-ratio):2.0663128
Number of Samples:3 / 4
Experimental expO kidney cancer study 1 (renal cell carcinoma, sarcomatoid; primary)
Primary tumor tissue samples obtained from the kidney of patients with renal cell carcinoma, sarcomatoid.
Control expO kidney cancer study 1 (granular cell carcinoma; primary)
Primary tumor tissue samples obtained from the kidney of patients with granular cell carcinoma.

AGR2 depletion study 1 / control siRNA transfected FA6 cell sample

Relative Expression (log2-ratio):-2.0370588
Number of Samples:3 / 3
Experimental AGR2 depletion study 1
Human pancreatic cancer cell line FA6 transiently transfected with AGR2 siRNA. Cells were transfected using INTERFERin 48 hours before RNA extraction and maintained in DMEM with 10% FBS.
Control control siRNA transfected FA6 cell sample
Control sample of pancreatic cancer cell line FA6 transiently transfected with non-targeting siRNA. Cells were analyzed 48 h after transfection.

Organism: Homo sapiens
Gene: 1318_at
Selected probe(set): 237333_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1318_at (237333_at) across 6593 perturbations tested by GENEVESTIGATOR:

lung cancer study 1 (PDX; non-small cell carcinoma; primary) / lung cancer study 1 (PDX; basaloid carcinoma; primary)

Relative Expression (log2-ratio):3.4635077
Number of Samples:2 / 3
Experimental lung cancer study 1 (PDX; non-small cell carcinoma; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary non-small cell carcinoma of the lung (subcutaneously implanted).
Control lung cancer study 1 (PDX; basaloid carcinoma; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary basaloid carcinoma of the lung (subcutaneously implanted).

ovarian tumor study 30 (PDX; mixed tumor, malignant, NOS; primary) / ovarian tumor study 30 (PDX; clear cell adenocarcinoma, NOS; primary)

Relative Expression (log2-ratio):-2.936082
Number of Samples:2 / 2
Experimental ovarian tumor study 30 (PDX; mixed tumor, malignant, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary mixed tumor, malignant, NOS of the ovary (subcutaneously implanted).
Control ovarian tumor study 30 (PDX; clear cell adenocarcinoma, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary clear cell adenocarcinoma, NOS of the ovary (subcutaneously implanted).

glioma study 17 (glioblastoma; A2B5+) / non-tumor oligodendrocyte progenitor cell sample (cortex)

Relative Expression (log2-ratio):2.8795862
Number of Samples:3 / 3
Experimental glioma study 17 (glioblastoma; A2B5+)
Oligodendrocyte progenitor cells (OPC) isolated from high grade glioblastoma (grade IV). OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. Patients were 66 ± 5 years old males.
Control non-tumor oligodendrocyte progenitor cell sample (cortex)
Oligodendrocyte progenitor cells (OPC) isolated from cortical tissue, which was obtained from patients with epilepsy, but without any manifested brain cancer. OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen.

brefeldin A study 1 (0.5ug/ml; p53HCT116) / untreated p53HCT116 cell sample

Relative Expression (log2-ratio):2.8112001
Number of Samples:2 / 3
Experimental brefeldin A study 1 (0.5ug/ml; p53HCT116)
Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:---
Control untreated p53HCT116 cell sample
Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS.

nephroblastoma study 2 / normal kidney tissue

Relative Expression (log2-ratio):2.745017
Number of Samples:4 / 3
Experimental nephroblastoma study 2
Tumor tissue samples from the kidney of patients with Wilms’ tumor.
Control normal kidney tissue
Normal adult kidney tissue samples.

B-CLL study 11 (rolipram) / rolipram study 4 (normal B-cell; 20uM)

Relative Expression (log2-ratio):2.7260885
Number of Samples:4 / 4
Experimental B-CLL study 11 (rolipram)
Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l. ATC code:---
Control rolipram study 4 (normal B-cell; 20uM)
MACS purified resting B-cells from healthy donor peripheral blood treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. ATC code:---

ovarian tumor study 30 (PDX; clear cell adenocarcinoma, NOS; primary) / ovarian tumor study 30 (PDX; adenocarcinoma, NOS; primary)

Relative Expression (log2-ratio):2.7259312
Number of Samples:2 / 2
Experimental ovarian tumor study 30 (PDX; clear cell adenocarcinoma, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary clear cell adenocarcinoma, NOS of the ovary (subcutaneously implanted).
Control ovarian tumor study 30 (PDX; adenocarcinoma, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary adenocarcinoma, NOS of the ovary (subcutaneously implanted).

4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone study 1 (7500 uM; HepaRG) / vehicle (DMSO) treated HepaRG cell sample

Relative Expression (log2-ratio):-2.646655
Number of Samples:3 / 12
Experimental 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone study 1 (7500 uM; HepaRG)
HepaRG cells exposed to 7500 uM 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (dissolved in 0.5% v/v DMSO) for 72 hours. Cells were cultivated in DMSO-containing medium between days 13 - 19 to allow them to differentiate into hepatocyte-like cells and become fully functional. Chemical was added at day 19 of cultivation. Cells were treated with the IC10 determined by a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide test (number of replicates, n = 3). ATC code:---
Control vehicle (DMSO) treated HepaRG cell sample
HepaRG cells treated with vehicle (DMSO 0.5% v/v) for 72 hours. Firstly, cells were cultivated in DMSO-containing medium between days 13 - 19 to allow them to differentiate into hepatocyte-like cells and become fully functional. Then the vehicle was added.

HCC study 27 (young; validation) / HCC study 27 (elder; validation)

Relative Expression (log2-ratio):2.5289173
Number of Samples:21 / 10
Experimental HCC study 27 (young; validation)
Primary tumor tissue samples obtained from the liver of young patients (≤ 40 years old) with hepatocellular carcinoma assigned to a validation cohort.
Control HCC study 27 (elder; validation)
Primary tumor tissue samples obtained from the liver of elder patients (> 40 years old) with hepatocellular carcinoma assigned to a validation cohort.

B-CLL study 11 (DMSO) / vehicle (DMSO) treated normal B-cell sample

Relative Expression (log2-ratio):2.5132132
Number of Samples:4 / 4
Experimental B-CLL study 11 (DMSO)
Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with vehicle (DMSO) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l.
Control vehicle (DMSO) treated normal B-cell sample
MACS purified resting B-cells from healthy donor peripheral blood treated with vehicle (DMSO) for 4 hours.